Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage

Journal of Human Hypertension

Volumn 12, Issue 5, 1998, Pages 301-309

  Nishikawa, K ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

5 6 nephrectomised rats; AT1 receptor antagonism; Candesartan cilexetil; DOCA salt hypertensive rats; End organ damage; SHRSP

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; GLOMERULOSCLEROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY FAILURE; MALE; MESANGIUM CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL NEPHRECTOMY; RAT; STROKE; ANIMAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DISEASE MODEL; DRUG ANTAGONISM; NEPHRECTOMY; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; HYPERTENSION; LOSARTAN; MALE; NEPHRECTOMY; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0031595541     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000634     Document Type: Conference Paper

References (41)

1. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′- (1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
2. Inada Y et al. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 (AT1)-receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 1994; 268: 1540-1547.
3. Inada Y et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exper Hypertension 1997; 19: 1079-1099.
4. Kim S et al. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Intern 1994; 46: 1346-1358.
5. Kim S et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995; 273: 509-515.
6. Wada T et al. Role of angiotensin II in cerebrovascular and renal damages in DOCA/salt hypertensive rats. J Hypertens 1995; 24: 113-122.
7. Kim S et al. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994; 24: 195-204.
8. Noda M et al. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Intern 1997; 52 (Suppl 63): S136-S139.
9. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 1974; 34/35 (Suppl 1): I-134-I145.
10. 3 site ligand: a critical analysis of animal models of cerebral ischemia and neurodegeneration. Brain Res 1990; 522: 275-289.
11. Fornes P et al. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22: 305-313.
12. Okada M et al. Effect of chronic treatment with losartan on development of hypertension in stroke-prone spontaneously hypertensive rats (SHRSP): Comparative study with enalapril and hydralazine. Hypertens Res Clin Exp 1993; 16: 49-55.
13. Camargo MJF et al. Control of blood pressure and endorgan damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993; 11: 31-40.
14. Stier CT et al. Stroke-prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 (Suppl 3): S37-S42.
15. Nakamura T et al. Renal protective effects of angiotensin II receptor I antagonist CV-11974 in spontaneously hypertensive stroke-prone rats (SHR-sp). Blood Press 1994; 3 (Suppl 5): 61-66.
16. Oddie CJ, Dilley RJ, Bobik A. Long-term angiotensin II antagonism in spontaneously hypertensive rats. Effects on blood pressure and cardiovascular amplifiers. Clin Exp Pharmacol Physiol 1992; 19: 392-395.
17. Mizuno K et al. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992; 51: 367-374.
18. Mizuno K et al. TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue reninangiotensin system in spontaneously hypertensive rats. Life Sci 1994; 54: 1987-1994.
19. Kojima M et al. Angiotensin II receptor antagonist TCV-116 induces the regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intra-cellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994; 89: 2204-2211.
20. Takeda K et al. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press 1994; 3 (Suppl 5): 94-98.
21. Kagoshima T et al. Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Press 1994; 3 (Suppl 5): 89-93.
22. Kohya T et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: beneficial effect of angiotensin II blockade. Circ Res 1995; 76: 892-899.
23. Fujita H et al. The role of angiotensin II in hypertensive cardiac hypertrophy and impaired coronary circulation. Respr Circ 1995; 43: 181-185.
24. Von Lutterotti N et al. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. J Hypertens 1992; 10: 949-957.
25. De Simone G et al. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996; 9: 216-222.
26. Ideishi M et al. Comparative effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Dahl rats. Blood Press 1994; 3 (Suppl 5): 99-104.
27. Lafayette RA et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
28. Shibouta Y et al. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Intern 1996; 49 (Suppl 55): S-115-S-118.
29. Mackenzie HS et al. TCV-116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens 1994; 12 (Suppl 9): S11-S16.
30. Hirata Y et al. Effect of an AT1 receptor antagonist (CV-11974) on angiotensin II-induced cardiomyocyte hypertrophy in vitro. Blood Press 1994; 3 (Suppl 5): 84-88.
31. ++-growth coupling in angiotensin II-induced hypertrophy in cultured rat cardiac cells. Cardiovasc Res 1995; 30: 419-431.
32. Schorb W et al. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993; 72: 1245-1254.
33. Brilla CG et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-820.
34. Crabos M et al. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts; coupling to signaling systems and gene expression. J Clin Invest 1994; 93: 2372-2378.
35. Anderson PW, Do YS, Hsueh WA. Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993; 21: 29-35.
36. 1 receptors. Kidney Int 1994; 45: 177-184.
37. Orth SR et al. Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 1995; 3: 23-33.
38. Sachinidis S et al. EXP-3174, a metabolite of losartan (MK954, DuP753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens 1993; 11: 155-162.
39. Sudhir K et al. Mechanical strain and collagen potentiate mitogenic activity of angiotensin II in rat vascular smooth muscle cells. J Cell Invest 1993; 92: 3003-3007.
40. Briand V et al. Characterization of the angiotensin II ATI receptor subtype involved in DNA synthesis in cultured vascular smooth muscle cells. Br J Pharmacol 1994; 112: 1195-1201.
41. Sachinidis S et al. CV-11974, the active metabolite of TCV-116 (candesartan), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells. Biochem Pharmacol 1996; 52: 123-126.